E. Buchbinder

Oncology · Nature · 2016–2023

A researcher in the Science corpus: 5 papers; trusts 6 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom E. Buchbinder trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Lieping Chen
  2. C. Robert
  3. D. Pardoll
  4. E. Wherry
  5. F. Hodi
  6. G. Freeman
  7. M. Keir
  8. M. Butte
  9. W. Zou
  10. B. Fife

Who trusts E. Buchbinder overall

  1. Ruixue Huang

Papers from E. Buchbinder's perspective

Ordered by how strongly the researchers E. Buchbinder trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  2. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
  3. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  4. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  5. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. (Immunity)
  6. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
  7. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (Nature)
  8. The B7 family revisited. (Annual Review of Immunology)
  9. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)
  10. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (Nature)

Their papers